Speaker 1:
Kika Veljkovic is a clinical biochemist living and working in Ontario. She is a graduate of the Postdoctoral Training Program in Clinical Biochemistry at McMaster University and a fellow of the Canadian Academy of Clinical Biochemistry. She is professionally involved with the Institute for Quality Management in Healthcare, as chair of the IQMH Endocrinology and Immunology Scientific Committee, and is a part-time faculty in the Department of Pathology and Molecular Medicine at McMaster University. She joined LifeLabs laboratory 12 years ago as a staff clinical biochemist, later moving into the role of Discipline Head for high volume chemistry, which includes core chemistry and immunochemistry, urinalysis, HbA1c testing and FIT.
Topic 1:
Implementation of CKD-EPI 2021 and KFRE in Ontario community laboratories – expected impact on eGFR results and referral to nephrology
Overview, Topic 1:
This presentation will describe the implementation of CKD-EPI 2021 equation for estimated glomerular filtration rate (eGFR) and Kidney Failure Risk Equation (KFRE) in two large Ontario community laboratories. CKD-EPI 2021 and KFRE were introduced in Ontario community laboratories as part of the Ontario Health (Ontario Renal Network) efforts aimed to encourage appropriate diagnosis and management of chronic kidney disease in primary care. We assessed the expected eGFR result changes and the nephrology referral rates in the population served by community laboratories in Ontario.
Learning Objectives, Topic 1:
At the conclusion of this session, participants will be able to:
- describe KFRE and its use in CKD.
- understand the recent changes in reporting of kidney function tests in Ontario.
- discuss the results of a study evaluating the impact of these changes on eGFR results and referral to nephrology in a large community laboratory cohort.
Speaker 2:
Matthew Nichols is a clinical biochemist at London Health Sciences Centre where he oversees trace elements, therapeutic drug monitoring and toxicology. His focus is on clinical applications of different mass spectrometry platforms.
Topic 2:
Analyzing M-proteins by Mass spectrometry: A view from the driver’s seat
Overview, Topic 2:
This presentation will quickly cover our M-protein method including sample preparation with the liquid handler, LC-QTOF data acquisition and data analysis. The focus of this presentation will be on data analysis where the screen will be shared as we work through a QC (positive and negative), 1 patient for GAMKL and a reagent blank as if you were the biochemist signing the case out.
The primary goal will be to showcase the software functionality as if you were the biochemist responsible for the interpretation of the results. A view from the driver’s seat.
Learning Objectives, Topic 2:
At the conclusion of this session, participants will be able to:
- gain introduction to M-protein analysis by mass spectrometry.
- demonstrate software functionality.
- see data analysis from the view of the interpreting biochemist.